Mexico Atherosclerosis Therapeutics Market Analysis

Mexico Atherosclerosis Therapeutics Market Executive Summary

Mexico Atherosclerosis Therapeutics Market was valued at $42 Mn in 2022 and is estimated to reach $67 Mn in 2030, exhibiting a CAGR of 5.95% during the forecast period.

Atherosclerosis is a condition characterized by the buildup of plaque, which is a sticky substance made of cholesterol, fat, calcium, and other materials, inside the walls of arteries. This buildup can lead to the narrowing or obstruction of blood vessels, reducing blood flow and increasing the risk of serious conditions such as heart attacks and strokes. The development of atherosclerosis is influenced by various factors, including high blood pressure, elevated cholesterol levels, diabetes, obesity, smoking, a family history of heart disease, physical inactivity, and an unhealthy diet. Several drugs have demonstrated effectiveness in reducing or preventing the progression of atherosclerosis, including beta-blockers, aspirin, and statins.

In Mexico, atherosclerosis is an important health issue and accounts for a considerable share of the burden of cardiovascular disease (CVD). At least one atherosclerosis risk factor, such as high cholesterol, obesity, or diabetes, is present in almost 30% of adult Mexicans. Cardiovascular disease (CVD) is Mexico's leading cause of death, accounting for almost one-third of all fatalities. Conditions associated with atherosclerosis, such as stroke and coronary artery disease, are major contributors to this. The population of Mexico is aging quickly, which increases the country's vulnerability to chronic illnesses like atherosclerosis. Mexico's shift to an urban lifestyle has resulted in an increase in unhealthy eating habits, physical inactivity, and smoking, all of which increase the risk of atherosclerosis. Susceptibility is also influenced by genetic factors; certain populations may be more inclined than others because of their background.

Merck Sharp & Dohme (MSD) and the Mexican Association of Cardiology (AMC) established a strategic relationship to launch influential educational programs centred on the management and prevention of cardiovascular illnesses, with a particular focus on atherosclerosis. The Mexican Ministry of Health announced a ground-breaking research partnership with prestigious academic institutions and pharmaceutical firms. This collaboration demonstrates a noteworthy dedication to improving cardiovascular health by promoting novel approaches for the early identification and treatment of atherosclerosis.

Market Dynamics

Market Growth Drivers

Aging Population: There is a growing need for atherosclerosis-related therapeutics since the aging of the population greatly increases the susceptibility of the elderly to atherosclerosis. Mexico's elderly population is expanding at a greater rate than the country's total population. This age group is expected to double or even triple by 2050, reaching about 40 Mn people, before peaking in 2085 at 48.3 Mn. Since atherosclerosis is more common in the elderly population, there is an increasing need to address the condition's therapeutic needs.

Increasing Cardiovascular Disease Burden: One of the main causes of CVD, atherosclerosis, is largely responsible for the rising need for alternative forms of treatment. Almost 30% of adult Mexicans have at least one atherosclerosis risk factor, such as high cholesterol, obesity, or diabetes. Better atherosclerosis treatment methods are required in addition to the growing burden of CVD and the increasing incidence of risk factors such as diabetes, high blood pressure, and unhealthy cholesterol levels.

Increased Awareness and Early Diagnosis: One major factor driving the expansion of the atherosclerosis treatment drug market is the focus on early diagnosis and increased awareness in programs like the educational initiatives by Merck Sharp & Dohme (MSD) and the research partnership with the Mexican Ministry of Health. Early detection and intervention in cases of atherosclerosis is achieved through public awareness initiatives and improved diagnostic technologies. This, in turn, can expand the market for preventive medications, as a proactive approach to addressing cardiovascular health becomes more widespread, contributing to the overall growth of the atherosclerosis treatment drug market.

Market Restraints

Lack of Awareness: An inadequate understanding of atherosclerosis and associated preventive measures may make it challenging to intervene early and discourage patients from seeking care as soon as possible. People who lack knowledge of atherosclerosis and its prevention strategies may fail to identify the disease's symptoms or act promptly to take preventive action, which could prolong the need for medical intervention and care. The growth of the market is hampered by this lack of knowledge.

Regulatory Hurdles: Pharmaceutical businesses may face challenges and additional expenses as a result of lengthy clinical trials and stringent regulatory procedures, which can postpone the release of new drugs into the market. The uncertainty produced by ambiguous regulations may make it difficult for businesses to plan for approval dates and to operate the system effectively. Because of the ambiguity surrounding the regulatory approval process, innovators find it challenging to estimate requirements and review timelines. This complexity can cause serious delays in the development of new medications by requiring meticulous planning and coordination at multiple stages, including as clinical trials, manufacturing, and marketing approval. Uncertainty in regulations prevents the market from expanding.

High Drug Cost: A significant barrier for many people, especially those with lower incomes or less access to healthcare, is the high cost of the medications used to treat atherosclerosis. High prescription medication costs are an issue since they limit market penetration and impede overall growth.

Healthcare Policies and Regulatory Landscape

The Federal Committee for the Protection against Sanitary Risk (COFEPRIS), which operates within the Secretariat of Health, is in charge of regulating therapeutic drugs and healthcare policy in Mexico. Pharmaceutical businesses are required to go through a stringent registration and approval process with COFEPRIS in order to guarantee the quality, safety, and efficacy of treatment medications. Strict quality control methods are enforced by the regulatory body, which also examines manufacturing sites and only authorizes marketing after rigorous assessments. COFEPRIS continues to be actively involved in post-marketing surveillance, keeping an eye out for negative reactions and making sure that compliance is maintained. Government initiatives and healthcare programs have a crucial role in establishing the landscape of pharmaceutical access for the public. Policies pertaining to healthcare outside regulatory elements may also impact the pricing and accessibility of treatment drugs in Mexico.

Competitive Landscape

Key Players

• Pfizer
• Novartis
• AstraZeneca
• Sanofi
• Bayer
• Abbott
• Johnson & Johnson
• Teva Pharmaceutical
• Roche
• Merck & Co.